Article
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.
Nature communications - 1 Dec 2023
Liu Ning Qing, Paassen Irene, Custers Lars, Zeller Peter, Teunissen Hans, Ayyildiz Dilara, He Jiayou, Buhl Juliane Laura, Hoving Eelco Wieger, van Oudenaarden Alexander, de Wit Elzo, Drost Jarno
Abstract excerpt
Malignant rhabdoid tumor (MRT) is a highly malignant and often lethal childhood cancer. MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of the BRG1/BRM-associated factors (BAF) chromatin remodeling complex. Mutations in BAF complex members are common in human cancer, yet their contribution to tumorigenesis remains in many cases poorly understood. Here, we study derailed...
Topics
- Humans
- Child
- Rhabdoid Tumor
- SMARCB1 Protein
- Transcription Factors
- Mutation
- Promoter Regions, Genetic
- Carcinogenesis